相关实验视频

Updated: May 4, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在复发性/耐火性髓质瘤中使用卢斯帕特塞普的长期经验:一项中国现实世界研究

Zhuxin Zhang¹, Leyu Wang¹, Ziwei Liu¹

¹Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.

Advances in therapy

|March 2, 2025

概括

卢斯帕特塞普特有效治疗复发性或耐火性低风险骨髓发育瘤 (LR-MDS),改善血红蛋白,减少输血需求. 长期数据显示,在现实世界中的亚洲患者中,持续有效性和良好的安全性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床研究临床研究

背景情况:

卢斯帕特塞普特在较低风险的骨髓分裂性瘤 (LR-MDS) 中显示出有效性.
在LR-MDS中,特别是亚洲,对luspatercept的实际长期随访数据有限.

研究的目的:

评估亚洲患有复发或耐药LR-MDS的患者中luspatercept的长期疗效和安全性.
评估血液学改善和输血独立率.
为了确定治疗反应的预测因素.

主要方法:

从60名用luspatercept治疗的复发/耐药LR-MDS患者回顾性收集数据.
在2022年6月至2024年5月期间收集的数据.
血液学改善-红色素 (HI-E) 率,输血独立性,血红蛋白水平和疾病进展的分析.

主要成果:

血液学改善-红色素 (HI-E) 率在3个月后为46.7%,在随访结束时为43.3%.
48.3%的输血依赖患者在6个月内实现了≥8周的输血独立.
观察到显著的血红蛋白增加;低基线红素 (EPO) 是HI-E的预测因素.

结论:

卢斯帕特塞普特在亚洲现实环境中的复发/耐药LR-MDS患者中有效且耐受良好.
该药物显示出降低疾病进展和延长生存时间的潜力.
卢斯帕特塞普特为这种患者群体提供了一种有益的治疗选择.

关键词:

影响影响影响影响影响长期的长期的长期的较低风险的骨髓分裂性瘤.卢斯帕特接受了这种感觉.耐火的耐火的耐火的

更多相关视频

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...